Acute neuro-Behçet’s disease with longitudinal extensive transverse myelitis in a patient receiving long-term anti-TNF-α therapy

References

• Yazici H, Seyahi E, Hatemi G, et al. Behçet syndrome: a contemporary view. Nat Rev Rheumatol. 2018;14:107–119.
   PubMed Web of Science ®Google Scholar
• Miller JJ, Venna N, Siva A. Neuro-Behçet disease and autoinflammatory disorders. Semin Neurol. 2014;34:437–443.
   Web of Science ®Google Scholar
• Noel N, Bernard R, Wechsler B, et al. Long-term outcome of neuro-Behçet’s disease. Arthritis Rheumatol. 2014;66:1306–1314.
   PubMed Web of Science ®Google Scholar
• Hirohata S, Kikuchi H, Sawada T, et al. Clinical characteristics of neuro-Behcet’s disease in Japan: a multicenter retrospective analysis. Mod Rheumatol. 2012;22:405–413.
   PubMed Web of Science ®Google Scholar
• Al-Araji A, Kidd DP. Neuro-Behçet’s disease: epidemiology, clinical characteristics, and management. Lancet Neurol. 2009;8:192–204.
   PubMed Web of Science ®Google Scholar
• Yesilot N, Mutlu M, Gungor O, et al. Clinical characteristics and course of spinal cord involvement in Behçet’s disease. Eur J Neurol. 2007;14:729–737.
   PubMed Web of Science ®Google Scholar
• Liu HM, Dong C, Zhang YZ, et al. Clinical and imaging features of spinal cord type of neuro Behçet disease: a case report and systematic review. Medicine (Baltimore). 2017;96:e7958.
   PubMed Web of Science ®Google Scholar
• Vallet H, Riviere S, Sanna A, et al. Efficacy of anti-TNF alpha in severe and/or refractory Behçet’s disease: multicenter study of 124 patients. J Autoimmun. 2015;62:67–74.
   PubMed Web of Science ®Google Scholar
• Pipitone N, Olivieri I, Padula A, et al. Infliximab for the treatment of Neuro-Behçet’s disease: a case series and review of the literature. Arthritis Rheum. 2008;59:285–290.
   PubMed Web of Science ®Google Scholar
• Borhani Haghighi A, Safari A, Nazarinia MA, et al. Infliximab for patients with neuro-Behcet’s disease: case series and literature review. Clin Rheumatol. 2011;30:1007–1012.
   PubMed Web of Science ®Google Scholar
• Desbois AC, Addimanda O, Bertrand A, et al. Efficacy of anti-TNFα in severe and refractory neuro-behcet disease: an observational study. Medicine (Baltimore). 2016;95:e3550.
   PubMed Web of Science ®Google Scholar
• Hibi T, Hirohata S, Kikuchi H, et al. Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease: efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore). 2016;95:e3863.
   PubMed Web of Science ®Google Scholar
• Coulter I, Huda S, Baborie A, et al. Longitudinally extensive transverse myelitis as the sole presentation of neuro-Behçet’s disease responding to infliximab. J Spinal Cord Med. 2012;35:122–124.
   PubMed Web of Science ®Google Scholar
• Kuroda R, Suzuki J, Muramatsu M, et al. Efficacy of infliximab in neuro-Behçet’s disease presenting with isolated longitudinally extensive transverse myelitis. J Neurol. 2013;260:3167–3170.
   Web of Science ®Google Scholar
• Uygunoğlu U, Pasha M, Saip S, et al. Recurrent longitudinal extensive transverse myelitis in a neuro-Behçet syndrome treated with infliximab. J Spinal Cord Med. 2015;38:111–114.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Contatore M, et al. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? Expert Opin Drug Saf. 2016;15:43–52.
   PubMed Web of Science ®Google Scholar
• Neves FS, Ferreira RM, Pereira IA, et al. Neuro-Behçet’s disease, its mimickers and anti-TNF therapy: a case-based review. Clin Exp Rheumatol. 2013;31:133–140.
   Web of Science ®Google Scholar
• Kemanetzoglou E, Andreadou E. CNS demyelination with TNF-α blockers. Curr Neurol Neurosci Rep. 2017;17:36.
   PubMed Web of Science ®Google Scholar
• Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum. 2001;44:2862–2869.
   PubMed Web of Science ®Google Scholar
• Seror R, Richez C, Sordet C, et al. Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey. Rheumatology. 2013;52:868–874.
   PubMed Web of Science ®Google Scholar
• Al Saieg N, Luzar MJ. Etanercept induced multiple sclerosis and transverse myelitis. J Rheumatol. 2006;33:1202–1204.
   PubMed Web of Science ®Google Scholar
• Kameda T, Dobashi H, Kittaka K, et al. A case of rheumatoid arthritis complicated by demyelination in both cerebral cortex and spinal cord during etanercept therapy. Mod Rheumatol. 2008;18:399–402.
   PubMed Web of Science ®Google Scholar
• Caracseghi F, Izquierdo-Blasco J, Sanchez-Montanez A, et al. Etanercept-induced myelopathy in a pediatric case of blau syndrome. Case Rep Rheumatol. 2011;2011:134106.
   PubMedGoogle Scholar
• Defty H, Sames E, Doherty T, et al. Case report of transverse myelitis in a patient receiving etanercept for rheumatoid arthritis. Case Rep Rheumatol 2013;2013:728371.
   Google Scholar
• Akman-Demir G, Serdaroglu P, Tasçi B. Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients. The Neuro-Behçet Study Group. Brain. 1999;122:2171–2182.
   PubMed Web of Science ®Google Scholar
• Kidd D, Steuer A, Denman AM, et al. Neurological complications in Behçet’s syndrome. Brain. 1999;122:2183–2194.
   PubMed Web of Science ®Google Scholar
• Ideguchi H, Suda A, Takeno M, et al. Neurological manifestations of Behçet’s disease in Japan: a study of 54 patients. J Neurol. 2010;257:1012–1020.
   PubMed Web of Science ®Google Scholar
• Hirohata S, Isshi K, Oguchi H, et al. Cerebrospinal fluid interleukin-6 in progressive Neuro-Behçet’s syndrome. Clin Immunol Immunopathol. 1997;82:12–17.
   PubMedGoogle Scholar
• Akman-Demir G, Tüzün E, Içöz S, et al. Interleukin-6 in neuro-Behçet's disease: association with disease subsets and long-term outcome. Cytokine. 2008;44:373–376.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Roberto-Perez-Alvarez DLC, Cuadrado MJ, et al. BIOGEAS study group. Autoimmune diseases induced by biological agents: a double-edged sword? Autoimmun Rev 2010;9:188–193.
   PubMed Web of Science ®Google Scholar
• Kaltsonoudis E, Zikou AK, Voulgari PV, et al. Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study. Arthritis Res Ther. 2014;16:R125.
   PubMed Web of Science ®Google Scholar
• Hirohata S. Histopathology of central nervous system lesions in Behçet’s disease. J Neurol Sci. 2008;267:41–47.
   PubMed Web of Science ®Google Scholar
• Kikuchi H, Aramaki K, Hirohata S. Effect of infliximab in progressive neuro-Behçet’s syndrome. J Neurol Sci. 2008;272:99–105.
   PubMed Web of Science ®Google Scholar
• Frassanito MA, Dammacco R, Cafforio P, et al. Th1 polarization of the immune response in Behçet’s disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum. 1999;42:1967–1974.
   PubMed Web of Science ®Google Scholar
• Mege JL, Dilsen N, Sanguedolce V, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behçet’s disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993;20:1544–1549.
   PubMed Web of Science ®Google Scholar
• Yamashita N, Kaneoka H, Kaneko S, et al. Role of gammadelta T lymphocytes in the development of Behçet’s disease. Clin Exp Immunol. 1997;107:241–247.
   PubMed Web of Science ®Google Scholar
• Freysdottir J, Lau S, Fortune F. Gammadelta T cells in Behçet’s disease (BD) and recurrent aphthous stomatitis (RAS). Clin Exp Immunol. 1999;118:451–457.
   PubMed Web of Science ®Google Scholar
• Accardo-Palumbo A, Giardina AR, Ciccia F, et al. Phenotype and functional changes of Vgamma9/Vdelta2 T lymphocytes in Behçet’s disease and the effect of infliximab on Vgamma9/Vdelta2 T cell expansion, activation and cytotoxicity. Arthritis Res Ther. 2010;12:R109.
   PubMed Web of Science ®Google Scholar
• Fukae J, Noda K, Fujishima K, et al. Subacute longitudinal myelitis associated with Behcet’s disease. Intern Med. 2010;49:343–347.
   Web of Science ®Google Scholar
• Koçer N, Islak C, Siva A, et al. CNS involvement in neuro-Behçet syndrome: an MR study. AJNR Am J Neuroradiol. 1999;20:1015–1024.
   PubMed Web of Science ®Google Scholar
• Bitik B, Ucar M, Tezcan ME, et al. Transverse myelitis in Behçet’s disease: a series of four cases and review of the literature. Clin Exp Rheumatol. 2013;31:20–24.
   PubMed Web of Science ®Google Scholar
• Bruscolini A, Sacchetti M, La Cava M, et al. Diagnosis and management of neuromyelitis optica spectrum disorders – an update. Autoimmun Rev. 2018;17:195–200.
   PubMed Web of Science ®Google Scholar
• Patterson SL, Goglin SE. Neuromyelitis optica. Rheum Dis Clin North Am. 2017;43:579–591.
   PubMed Web of Science ®Google Scholar
• Karussis D. The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. J Autoimmun. 2014;48–49:134–142.
   PubMed Web of Science ®Google Scholar
• Greene DN, Schmidt RL, Wilson AR, et al. Cerebrospinal fluid myelin basic protein is frequently ordered but has little value: a test utilization study. Am J Clin Pathol. 2012;138:262–272.
   PubMed Web of Science ®Google Scholar
• Tian ZJ, Zhao XX, Li ZH, et al. Evaluation of myelin basic protein levels with receiver operating characteristic curves for diagnosis of multiple sclerosis. Nan Fang Yi Ke Da Xue Xue Bao. 2009;29:250–252.
   Google Scholar